Share on LinkedInShare on LinkedIn

ARTICLE · 02 MAY 2012

PMPRB Seeks More Efficient Use Of Its Resources

The Patented Medicine Prices Review Board is seeking stakeholder comments on proposed changes to its Compendium of Policies, Guidelines and Procedures related to thresholds for opening an investigation and offsetting de minimus excess revenues.

CanadaFood, Drugs, Healthcare, Life Sciences

The Patented Medicine Prices Review Board is seeking stakeholder comments on proposed changes to its Compendium of Policies, Guidelines and Procedures related to thresholds for opening an investigation and offsetting de minimus excess revenues.

With respect to thresholds for opening an investigation, the Board is proposing to eliminate the 5% investigation trigger at the national level for existing drug products. The present criterion for commencing an investigation for existing drug products when the National Average Transaction Price exceeds the Non-Excessive Average Price by 5% will trigger a high number of investigations with cumulative excess revenues that are less than $50,000. It is believed that the avoidance of investigations involving amounts of excess revenue less than $50,000 will result in a more efficient use of the Board's resources.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from